Tango Therapeutics (TNGX) Retained Earnings (2020 - 2026)

Tango Therapeutics' Retained Earnings history runs 7 years deep, the most recent figure standing at -$648.7 million for Q1 2026.

• In Q1 2026, Retained Earnings fell 334463.92% year-over-year to -$648.7 million; the TTM figure through Mar 2026 stood at -$648.7 million (down 334463.92% YoY), while the FY2025 annual figure was $224000.0, down 33.33% from the prior year.
• Retained Earnings was -$648.7 million for Q1 2026 at Tango Therapeutics, down from $224000.0 in the prior quarter.
• In the past five years, Retained Earnings ranged from a high of $336000.0 in Q4 2024 to a low of -$648.7 million in Q1 2026.
• Historically, Retained Earnings has averaged -$188.5 million across 5 years, with a median of -$186.5 million in 2022.
• The sharpest annual moves came in 2025 and 2026: Retained Earnings surged 128.14% in 2025, then tumbled 334463.92% in 2026.
• A 5-year view of Retained Earnings shows it stood at -$269.5 million in 2022, then slumped by 37.75% to -$371.3 million in 2023, then jumped by 100.09% to $336000.0 in 2024, then sank by 33.33% to $224000.0 in 2025, then sank by 289683.04% to -$648.7 million in 2026.
• The last three Retained Earnings figures came in at -$648.7 million (Q1 2026), $224000.0 (Q4 2025), and $121000.0 (Q3 2025), per Business Quant data.